CA2073084A1 - The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments - Google Patents

The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments

Info

Publication number
CA2073084A1
CA2073084A1 CA002073084A CA2073084A CA2073084A1 CA 2073084 A1 CA2073084 A1 CA 2073084A1 CA 002073084 A CA002073084 A CA 002073084A CA 2073084 A CA2073084 A CA 2073084A CA 2073084 A1 CA2073084 A1 CA 2073084A1
Authority
CA
Canada
Prior art keywords
preparation
combat
well
diseases
sulphur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002073084A
Other languages
French (fr)
Other versions
CA2073084C (en
Inventor
Heinz Ulrich
Helmut Hettche
Carl-Heinrich Weischer
Jurgen Engel
Harald Borbe
Wilfried Dimpfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2073084A1 publication Critical patent/CA2073084A1/en
Application granted granted Critical
Publication of CA2073084C publication Critical patent/CA2073084C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)

Abstract

The use of compounds of the formula (see formula one) where X is a hydrogen atom or both X represent a single bond between the two sulphur atoms and n is a number between 1 and or their therapeutically applicable salts for the preparation of a medicament to combat pathophysiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and the preparation of appropriate medicaments.
CA002073084A 1991-07-05 1992-07-03 The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments Expired - Lifetime CA2073084C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4122303 1991-07-05
DEP4122303.9 1991-07-05

Publications (2)

Publication Number Publication Date
CA2073084A1 true CA2073084A1 (en) 1993-01-06
CA2073084C CA2073084C (en) 2002-10-22

Family

ID=6435517

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002073084A Expired - Lifetime CA2073084C (en) 1991-07-05 1992-07-03 The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments

Country Status (9)

Country Link
EP (1) EP0530446B1 (en)
JP (1) JPH05213745A (en)
AT (1) ATE162715T1 (en)
CA (1) CA2073084C (en)
DE (2) DE59209162D1 (en)
DK (1) DK0530446T3 (en)
ES (1) ES2112874T3 (en)
GR (1) GR3026161T3 (en)
IE (1) IE922181A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531567B2 (en) 2001-05-28 2009-05-12 Serumwerk Bernburg Ag Use of a medicament containing an effector of the glutathione metabolism together with α-lipoic acid in kidney replacement therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4222826A1 (en) * 1992-07-09 1994-01-13 Schering Ag Medicines to prevent tolerance development during treatment with benzodiazepine receptor-binding agents
DE4317646A1 (en) * 1993-05-27 1994-12-01 Asta Medica Ag Tablets containing thioctic acid and at least one basic component
DE4327462A1 (en) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer N-Acetyl-p-aminophenol derivatives for controlling pain
DE4343592C2 (en) * 1993-12-21 1998-04-16 Asta Medica Ag Use of R - (+) - alpha-lipoic acid and its metabolites in the form of the free acid or as salts or esters or amides for the treatment of glucose metabolic disorders in the central nervous system
DE4433764A1 (en) 1994-09-22 1996-03-28 Asta Medica Ag Dosage forms containing alpha-lipoic acid, solid salts of R-thioctic acid with improved release and bioavailability
DE4439480C1 (en) * 1994-11-08 1996-06-05 Asta Medica Ag Use of D, L-alpha-lipoic acid and / or its enantiomers, and / or their derivatives as an additive in red cell liquid preserves for homologous and autologous erythrocyte concentrates and as an additive in erythrocyte cryoconserves for homologous and autologous erythrocyte concentrates
DE19806354B4 (en) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Use of α-lipoic acid or its physiologically tolerable salts for the treatment of LDL hypercholesterolemia
US6191162B1 (en) 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
JP4728481B2 (en) * 1998-10-26 2011-07-20 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク Lipoic acid derivatives and their use in the treatment of diseases
DE10027968A1 (en) * 2000-06-08 2001-12-13 Asta Medica Ag Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients
DE10258239A1 (en) * 2002-12-13 2004-06-24 Degussa Ag Formulation used for treating non-chronic alcoholic intoxication, contains alpha-lipoic acid for scavenging free radicals and activating alcohol metabolizing enzymes
DE10303229B4 (en) * 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol and Angiotensin Converting Enzyme (ACE) inhibitors Drugs and their use in the treatment of neurodegenerative diseases
JP4716666B2 (en) * 2003-05-21 2011-07-06 有限会社オガ リサーチ α-Lipoic acid-containing aqueous preparation
RU2423117C2 (en) * 2003-07-02 2011-07-10 Сергей Михайлович Зенович Medication for reducing rate of progressing, prevention of development, prevention of onset of pathological processes induced by intake of ethanol and/or substances possessing addictive potential
CN100422134C (en) * 2004-03-12 2008-10-01 北京天衡药物研究院 2-(alpha-n-pentanone) phenmethyl and its preparation process and application
JP2006321732A (en) * 2005-05-18 2006-11-30 Fancl Corp Removal of abnormal protein, and composition for suppressing increase of 8-hydroxy-2'-deoxyguanosine
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
DE102007038849A1 (en) 2007-08-16 2009-02-19 Adscil Gmbh Use of R (+) - alpha lipoic acid for the treatment of cryptogenic neuropathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70974T1 (en) * 1987-12-04 1992-01-15 Asta Pharma Ag INJECTABLE SOLUTION OF THIOCT ACID SALT WITH TROMETAMOLE AND/OR BASIC AMINO ACIDS.
JPH03188021A (en) * 1989-11-09 1991-08-16 Asta Pharma Ag Drug for combating retrovirus and its preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531567B2 (en) 2001-05-28 2009-05-12 Serumwerk Bernburg Ag Use of a medicament containing an effector of the glutathione metabolism together with α-lipoic acid in kidney replacement therapy

Also Published As

Publication number Publication date
JPH05213745A (en) 1993-08-24
DK0530446T3 (en) 1998-09-23
EP0530446A2 (en) 1993-03-10
DE4220851A1 (en) 1993-01-07
ATE162715T1 (en) 1998-02-15
EP0530446B1 (en) 1998-01-28
DE59209162D1 (en) 1998-03-05
ES2112874T3 (en) 1998-04-16
CA2073084C (en) 2002-10-22
GR3026161T3 (en) 1998-05-29
IE922181A1 (en) 1993-01-13
EP0530446A3 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
CA2073084A1 (en) The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
CA2007480A1 (en) Use of the active substance azelastine for the control of psoriasis disorders and inflammatory disorders
CA2036905A1 (en) Condensed thiazole compounds, their production and use
AU581442B2 (en) 2-substituted-1, 3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
EP0670319A4 (en) Heterocyclic compound.
HUT46536A (en) Process for producing antianxietive pharmaceutical compositions
AU1488392A (en) Pharmeceutical composition for the treatment of autoimmune diseases
ZA933455B (en) Thiochroman compounds, processes for the preparation thereof and pharmaceutical compositions containing them
CA2072106A1 (en) Cephalosporin compounds and method for producing them
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
AU621634B2 (en) Glycerin derivative and its pharmacological use
IL108246A0 (en) Nonatetraenoic acid derivates, their preparation and pharmaceutical compositions containing them
IL86846A (en) Pharmaceutical compositions for preventing and treating heart failure containing indane or naphthalene carboxylic acids
CA2065889A1 (en) Increasing the choroidal blood flow
EP0228239A3 (en) Preparation of a medicament for arthritis and rheumatism
TW258733B (en)
AU2013888A (en) Uricosuric composition
CA2127215A1 (en) New use of beta-naphtoquinone derivatives and of their salts for the production of a medicament to inhibit platelet aggregation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry